In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy

Journal of Biological Chemistry

Volumn 290, Issue 23, 2015, Pages 14441-14453

  Mishra, Rama K ^a   Wei, Changyong ^d   Hresko, Richard C ^b   Bajpai, Richa ^d   Heitmeier, Monique ^b   Matulis, Shannon M ^d   Nooka, Ajay K ^d   Rosen, Steven T ^c   Hruz, Paul W ^b   Schiltz, Gary E ^a   Shanmugam, Mala ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CELL MEMBRANES; CRYSTAL STRUCTURE; DISEASES; ENZYME INHIBITION; TUMORS;

ANTI-CANCER THERAPEUTICS; CHRONIC LYMPHOCYTIC LEUKEMIAS; GLUCOSE CONSUMPTION; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTERS; HIV-PROTEASE INHIBITORS; SELECTIVE INHIBITORS; THREE-DIMENSIONAL STRUCTURE;

GLUCOSE;

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 4 INHIBITOR; PROTEIN INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GLUCOSE; MOLECULAR LIBRARY;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CHEMOSENSITIZATION; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG DETERMINATION; DRUG STRUCTURE; EMBRYO; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DATABASE; DRUG DEVELOPMENT; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; ENZYME INHIBITORS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASMS; PROTEIN CONFORMATION; SMALL MOLECULE LIBRARIES;

EID: 84930643963     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.628826     Document Type: Article

References (51)

1. Durie, B. G., and Waxman., A. D., D'Agnolo, A., and Williams, C. M. (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J. Nucl. Med. 43, 1457-1463
2. Bredella, M. A., Steinbach, L., Caputo, G., Segall, G., and Hawkins, R. (2005) Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am. J. Roentgenol. 184, 1199-1204
3. Bartel, T. B., Haessler, J., Brown, T. L., Shaughnessy, J. D., Jr., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., Crowley, J., and Barlogie, B. (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114, 2068-2076
4. Castellani, M., Carletto, M., Baldini, L., Calori, R., Longari, V., Soligo, D., Dellavedova, L., and Gerundini, P. (2010) The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. Clin. Nucl. Med. 35, 1-5
5. Rodríguez-Enríquez, S., Marín-Hernández, A., Gallardo-Pérez, J. C., and Moreno-Sánchez, R. (2009) Kinetics of transport and phosphorylation of glucose in cancer cells. J. Cell. Physiol. 221, 552-559
6. Macheda, M. L., Rogers, S., and Best, J. D. (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202, 654-662
7. Chan, D. A., and Sutphin., P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J. T., Wu, J., Solow Cordero, D. E., Bonnet, M., Flanagan, J. U., Bouley, D.M., Graves, E.E., Denny, W. A., et al.(2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70
8. Manolescu, A. R., Witkowska, K., Kinnaird, A., Cessford, T., and Cheeseman, C. (2007) Facilitated hexose transporters: new perspectives on form and function. Physiology 22, 234-240
9. Maratou, E., Dimitriadis, G., Kollias, A., Boutati, E., Lambadiari, V., Mitrou, P., and Raptis, S. A. (2007) Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur. J. Clin. Invest. 37, 282-290
10. McBrayer, S. K., and Cheng., J. C., Singhal, S., Krett, N. L., Rosen, S. T., and Shanmugam, M. (2012) Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 119, 4686-4897
11. Murata, H., and Hruz., P. W., and Mueckler, M. (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275, 20251-20254
12. Adekola, K. U., Dalva Aydemir, S., Ma, S., Zhou, Z., and Rosen., S. T., and Shanmugam, M. (2015) Investigating and targeting chronic lymphocytic leukemia metabolism with the HIV protease inhibitor ritonavir and metformin. Leuk. Lymphoma 56, 450-459
13. Dalva-Aydemir, S., Bajpai, R., Martinez, M., Adekola, K. U., Kandela, I., Wei, C., Singhal, S., Koblinski, J. E., Raje, N. S., Rosen, S. T., and Shanmugam, M. (2015) Targeting the metabolic plasticity of multiple myeloma with FDA approved ritonavir and metformin. Clin. Cancer Res. 21, 1161-1171
14. Birnbaum, M. J. (1989) Identification of a novel gene encoding an insulinresponsive glucose transporter protein. Cell 57, 305-315
15. Mueckler, M., Caruso, C., Baldwin, S. A., Panico, M., Blench, I., and Morris., H. R., Allard, W. J., Lienhard, G. E., and Lodish, H. F. (1985) Sequence and structure of a human glucose transporter. Science 229, 941-945
16. Corvera, S., Chawla, A., Chakrabarti, R., Joly, M., Buxton, J., and Czech, M. P. (1994) A double leucine within the Glut4 glucose-transporter coohterminal domain functions as an endocytosis signal. J. Cell Biol. 126, 979-989
17. Oka, Y., Asano, T., Shibasaki, Y., Lin, J. L., Tsukuda, K., Katagiri, H., Akanuma, Y., and Takaku, F. (1990) C-terminal truncated glucose transporter is locked into an inward-facing form without transport activity. Nature 345, 550-553
18. Hebert, D. N., and Carruthers, A. (1992) Glucose transporter oligomeric structure determines transporter function. Reversible redox-dependent interconversions of tetrameric and dimeric GLUT1. J. Biol. Chem. 267, 23829-23838
19. Hertel, J., Struthers, H., Horj, C. B., and Hruz, P. W. (2004) A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J. Biol. Chem. 279, 55147-55152
20. Tripos (2011) SYBYL-X, Version 1.3, Tripos, St. Louis
21. Tordjman, K. M., and Leingang., K. A., James, D. E., and Mueckler, M. M. (1989) Differential regulation of two distinct glucose transporter species expressed in 3T3-L1 adipocytes: effect of chronic insulin and tolbutamide treatment. Proc. Natl. Acad. Sci. U.S.A. 86, 7761-7765
22. Piper, R. C., and Hess., L. J., and James, D. E. (1991) Differential sorting of two glucose transporters expressed in insulin-sensitive cells. Am. J. Physiol. 260, C570-C580
23. Hresko, R. C., and Kraft., T. E., Tzekov, A., Wildman, S. A., and Hruz, P. W. (2014) Isoform-selective inhibition of facilitative glucose transporters: elucidation of the molecular mechanism of HIV protease inhibitor binding. J. Biol. Chem. 289, 16100-16113
24. Ory, D. S., and Neugeboren., B. A., and Mulligan, R. C. (1996) A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U.S.A. 93, 11400-11406
25. Lemieux, M. J., and Huang., Y. F., and Wang, D. N. (2005) Crystal structure and mechanism of GlpT, the glycerol-3-phosphate transporter from E. coli. J. Electron Microsc. 54, 43-46
26. Guan, L., Mirza, O., Verner, G., Iwata, S., and Kaback, H. R. (2007) Structural determination of wild-type lactose permease. Proc. Natl. Acad. Sci. U.S.A. 104, 15294-15298
27. Yin, Y., He, X., Szewczyk, P., Nguyen, T., and Chang, G. (2006) Structure of the multidrug transporter EmrD from Escherichia coli. Science 312, 741-744
28. Schrödinger (2013) Maestro, Version 9.6, Prime 3.1, Schrödinger, LLC, New York
29. Chen, V. B., and Arendall., W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21
30. Davis, I. W., and Murray., L. W., Richardson, J. S., and Richardson, D. C. (2004) MolProbity: structure analysis and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32, W615-W619
31. Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., and Coleman, R. G. (2012) ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52, 1757-1768
32. Hann, M. M., and Oprea, T. I. (2004) Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8, 255-263
33. Baell, J. B. (2013) Broad coverage of commercially available lead-like screening space with fewer than 350,000 compounds. J. Chem. Inf. Model. 53, 39-55
34. Schrödinger (2011) Glide, Version 5.7, Schrödinger, LLC, New York
35. Deng, D., Xu, C, Sun, P., Wu, J., Yan, C, Hu, M., and Yan, N. (2014) Crystal structure of the human glucose transporter GLUT1. Nature 510, 121-125
36. Kyle, R. A., and Rajkumar, S. V. (2004) Multiple myeloma. N. Engl. J. Med. 351, 1860-1873
37. Richardson, P. G., Schlossman, R., Hideshima, T., and Anderson, K. C. (2005) New treatments for multiple myeloma. Oncology 19, 1781-1792
38. Munshi, N (2008) Plasma cell disorders: an historical perspective. Hematology 2008, 297
39. Xu, R. H., Pelicano, H., Zhang, H., Giles, F. J., Keating, M. J., and Huang, P. (2005) Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19, 2153-2158
40. Maschek, G., Savaraj, N, Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., and Lampidis, T. J. (2004) 2-Deoxy-Dglucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64, 31-34
41. Mohanti, B. K., and Rath., G. K., Anantha, N, Kannan, V., and Das., B. S., Chandramouli, B. A., Banerjee, A. K., Das, S., Jena, A., Ravichandran, R., Sahi, U. P., Kumar, R., Kapoor, N, and Kalia., V. K., Dwarakanath, B. S., and Jain, V. (1996) Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 35, 103-111
42. Cao, X., Fang, L., Gibbs, S., Huang, Y., Dai, Z., Wen, P., Zheng, X., Sadee, W, and Sun, D. (2007) Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol. 59, 495-505
43. Wright, E. M., and Loo., D. D., Panayotova-Heiermann, M., Lostao, M. P., Hirayama, B. H, Mackenzie, B., Boorer, K., and Zampighi, G. (1994) "Active" sugar transport in eukaryotes. J. Exp. Biol. 196, 197-212
44. Wright, E. M. (2001) Renal Na(+)-glucose cotransporters. Am. J. Physiol. Renal Physiol. 280, F10-F18
45. Ji, L., Ma, J., Li, H, and Mansfield., T. A., T'joen, C. L., Iqbal, N, Ptaszynska, A., and List, J. F. (2014) Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin. Ther. 36, 84-100
46. Ptaszynska, A., and Johnsson., K. M., Parikh, S. J., de Bruin, T. W., Apanovitch, A. M., and List, J. F. (2014) Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. DrugSaf. 37, 815-829
47. Yang, X. P., Lai, D., Zhong, X. Y., Shen, H. P., and Huang, Y. L. (2014) Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 70, 1149-1158
48. Han, S., and Hagan., D. L., Taylor, J. R., Xin, L., Meng, W., and Biller., S. A., Wetterau, J. R., Washburn, W. N, and Whaley, J. M. (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723-1729
49. Zhao, F. Q., and Keating, A. F. (2007) Functional properties and genomics of glucose transporters. Curr. Genomics 8, 113-128
50. Hresko, R. C, and Hruz, P. W. (2011) HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose-binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One 6, e25237
51. Vyas, A. K., Koster, J. C, Tzekov, A., and Hruz, P. W. (2010) Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J. Biol. Chem. 285, 36395-36400